ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design
![Capricor Announces Initiation of HOPE-2 Clinical Trial Of CAP-1002 for Duchenne Muscular Dystrophy - Action Duchenne Capricor Announces Initiation of HOPE-2 Clinical Trial Of CAP-1002 for Duchenne Muscular Dystrophy - Action Duchenne](https://www.actionduchenne.org/wp-content/uploads/2019/04/getimage-17.png)
Capricor Announces Initiation of HOPE-2 Clinical Trial Of CAP-1002 for Duchenne Muscular Dystrophy - Action Duchenne
![Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - ScienceDirect Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0140673622000125-gr2.gif)
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - ScienceDirect
![Capricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD) • BioTech Health X Capricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD) • BioTech Health X](https://biotechhealthx.com/wp-content/uploads/2021/09/Capricor-Therapeutics-To-Present-Final-HOPE-2-Trial-CAP-1002-Data-for-Late-Stage-Duchenne-Muscular-Dystrophy-DMD-1160x627.jpg)
Capricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD) • BioTech Health X
![Capricor & Nippon Shinyaku Enter Partnership for Commercialization and Distribution of CAP-1002 in the U.S. - Parent Project Muscular Dystrophy Capricor & Nippon Shinyaku Enter Partnership for Commercialization and Distribution of CAP-1002 in the U.S. - Parent Project Muscular Dystrophy](https://www.parentprojectmd.org/wp-content/uploads/2022/01/capricor-ns-blog2.png)
Capricor & Nippon Shinyaku Enter Partnership for Commercialization and Distribution of CAP-1002 in the U.S. - Parent Project Muscular Dystrophy
![1002-53 / Fuel Chrome Bolt-In Center Cap - 1002-53 - Fuel Center Caps - Custom Wheels for Trucks, Jeeps, SUVs and Passenger Cars 1002-53 / Fuel Chrome Bolt-In Center Cap - 1002-53 - Fuel Center Caps - Custom Wheels for Trucks, Jeeps, SUVs and Passenger Cars](https://www.customwheelsexpress.com/images/1002-53-A.jpg)
1002-53 / Fuel Chrome Bolt-In Center Cap - 1002-53 - Fuel Center Caps - Custom Wheels for Trucks, Jeeps, SUVs and Passenger Cars
![StudyPages - A Study of Experimental Cell Therapy (CAP-1002) in Patients With Duchenne Muscular Dystrophy (DMD) StudyPages - A Study of Experimental Cell Therapy (CAP-1002) in Patients With Duchenne Muscular Dystrophy (DMD)](https://yuzu-studypages-prod-east.s3.amazonaws.com/study_banners/1201.jpg)